Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial

Psychiatry and Clinical Neurosciences
Yuriko NinomiyaNoboru Yamaguchi

Abstract

The purpose of this study was to evaluate the long-term effectiveness and safety of blonanserin, a second-generation antipsychotic drug developed in Japan, in patients with first-episode schizophrenia. Twenty-three antipsychotic-naïve patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of blonanserin (2-24 mg/day). Clinical evaluations were conducted at baseline and 2, 6, and 12 months after the start of treatment. The main outcome measures were changes in subjective well-being and subjective quality of life, as assessed by the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version and the Schizophrenia Quality of Life Scale-Japanese version, respectively. Secondary outcome measures included the Positive and Negative Syndrome Scale, the Brief Assessment of Cognition in Schizophrenia-Japanese version, laboratory tests, bodyweight, and extrapyramidal symptoms. Fourteen patients (60.9%) remained on the study at 1 year. In the intention-to-treat analysis, significant improvements were observed in several subscales on the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version, the Schizophrenia Quality of Life Scale-Japanese ...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Feb 1, 1981·Archives of General Psychiatry·T Van PuttenL A Wittmann
Nov 1, 1994·The Journal of Nervous and Mental Disease·J P LindenmayerS Grochowski
Jun 1, 1996·Neuropsychologia·S C BakerT W Robbins
Dec 7, 2002·Psychiatry Research·Yasuhiro KanedaTetsuro Ohmori
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
Dec 18, 2007·Psychiatry and Clinical Neurosciences·Yasuhiro KanedaTetsuro Ohmori
Dec 29, 2007·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Krystyna GórnaJanusz K Rybakowski
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Jun 12, 2010·Early Intervention in Psychiatry·Sarah R UzenoffDavid L Penn
Mar 29, 2011·The Australian and New Zealand Journal of Psychiatry·Sylke VothknechtLieuwe de Haan
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
Mar 1, 2012·Psychiatry Research·Jong-Hoon KimZang-Hee Cho
Jul 10, 2012·Comprehensive Psychiatry·Gregory P StraussDaniel N Allen
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi

Citations

Sep 13, 2015·Pharmacology, Biochemistry, and Behavior·Ayaka TataraYukihiro Ohno
Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic

Related Concepts

Lonasen
Piperazines
Piperidines
Quality of Life
Schizophrenia
Antipsychotic Effect
Cognition
Laboratory Procedures
Memory
Schizophrenia

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here